The mean age of the patients at the start of the INF was years (range 2–20 years). At the initiation of INF, 62% (21/34) of patients were ≥10 years of age. The mean duration of uveitis prior to INF treatment was years (2–8 years). The mean duration of steroid treatment prior to start of disease modifying antirheumatic drugs (DMARD) therapy was 2 years (– years). Prior to INF therapy, all patients had been treated with steroids. This included 15/34 (44%) patients that received topical steroids and 19/34 (56%) patients that were on both topical and systemic steroids. The average dose of systemic steroid was mg/kg, and the maximum dose was 20 mg per day for a mean period of months. Topical prednisone administration varied significantly from every hour while awake to once a day. Based on the dosage given, there were 6 (18%) patients assigned to the LD group, 19 (56%) patients to the MD group, and 9 (26%) patients to the HD group. Dosing was determined by the primary pediatric rheumatologist on the basis of disease duration, disease activity at the time of presentation, and prior medication failures.
Corticosteroids have been used in MS treatment since the 1940’s, and their anti-inflammatory effect has been established in many studies. However, MS is a highly individualized disease, with no two people having the exact same experience or symptoms. There is great variability in the severity of relapses and the degree to which relapses respond to corticosteroid therapy. The research studies that have been conducted on corticosteroids vary, because not everyone initiates treatment with corticosteroids as soon as the relapse symptoms begin, so it’s difficult to predict how fast or how completely corticosteroids will work for the individual. 3